Biogen
BIIB
916 hedge funds and large institutions have $25.1B invested in Biogen in 2024 Q3 according to their latest regulatory filings, with 99 funds opening new positions, 270 increasing their positions, 378 reducing their positions, and 118 closing their positions.
0.51% more ownership
Funds ownership: 88.6% → 89.11% (+0.51%)
3% less funds holding
Funds holding: 943 → 916 (-27)
16% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 118
16% less capital invested
Capital invested by funds: $29.9B → $25.1B (-$4.82B)
24% less call options, than puts
Call options by funds: $214M | Put options by funds: $282M
29% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 378
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| 1 |
BlackRock
New York
|
+$169M |
| 2 |
Man Group
London,
United Kingdom
|
+$167M |
| 3 |
JP Morgan Chase
New York
|
+$113M |
| 4 |
Barclays
London,
United Kingdom
|
+$99.1M |
| 5 |
Two Sigma Investments
New York
|
+$91.2M |
Top Sellers
BIIB Hedge Fund Activity: Q3 2024 in Review
916 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2024, worth a combined $25.1B — down 16% from $29.9B a quarter earlier.
Sellers outnumbered buyers: 118 funds closed out of BIIB and 99 opened new positions — a net loss of 19 holders — while 378 trimmed existing stakes and 270 added.
The largest buyer was BlackRock, adding an estimated $169M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $298M.
- 916 institutional investors held Biogen (BIIB) as of Q3 2024, down from 943 in Q2 2024.
- Funds reported $25.1B of Biogen stock for Q3 2024, down 16% quarter-over-quarter.
- 99 funds opened new Biogen positions in Q3 2024 and 118 closed out, a net change of -19 holders.
- The largest Biogen buyer in Q3 2024 was BlackRock, an estimated $169M added.
- The largest Biogen seller in Q3 2024 was T. Rowe Price Investment Management, an estimated $298M sold.
Based on aggregated 13F filings for Q3 2024.